Investors

Latest Financial Results

Q3 2024

Quarterly Results

Ended Mar 31, 2024

Latest 10-K

Sign Up For E-Mail Alerts

Sign Up Today

Stock Information | View Detailed Stock Info

OTCPink: PPCB Propanc Biopharma, Inc.
Change
Volume
Day Range
52 Week Range

Company Overview

Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.

View Scientific Whitepaper

IR Contact Information

Investor Relations

Propanc Biopharma, Inc.
T: +61-03-9882-6723
irteam@propanc.com

Transfer Agent

Securities Transfer Corporation
2901 N. Dallas Parkway
Suite 380
Plano, Texas 75093
T: 469-633-0101
F: 469-633-0088
www.stctransfer.com